Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3739922 | 1.00 | EGLN1 (0.46) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL9582230 | 1.00 | EGLN1 (0.46) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3738082 | 0.98 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9582700 | 0.98 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9582091 | 0.98 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6874923 | 0.98 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3804263 | 0.98 | EGLN1 (0.44) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL23704593 | 0.91 | KDM4E (0.42) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10544160 | 0.87 | EGLN1 (0.46) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10544179 | 0.87 | EGLN1 (0.46) | EGLN1KDM4EALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | claimed |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| EP-4313159-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | Feldan Bio Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| EP-4229207-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | Feldan Bio Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| WO-2022204806-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-10-06 | — | — | WO | claimed |
| US-20220204561-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-06-30 | — | — | US | claimed |
| WO-2022082315-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2022-04-28 | — | — | WO | claimed |
| US-20190070153-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | CASE WESTERN RESERVE UNIVERSITY | 2019-03-07 | — | — | US | claimed |
| US-20180200233-A1 | COMPOSITIONS FOR PREVENTING CANCERS ASSOCIATED WITH HUMAN PAPILLOMA VIRUSES | LOMA LINDA UNIVERSITY | 2018-07-19 | — | — | US | claimed |
| EP-3322418-A1 | COMPOSITIONS FOR PREVENTING CANCERS ASSOCIATED WITH HUMAN PAPILLOMA VIRUSES | Loma Linda University (US) | 2018-05-23 | — | — | EP | claimed |
| WO-2017062988-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-04-13 | — | — | WO | claimed |
| WO-2017011473-A1 | COMPOSITIONS FOR PREVENTING CANCERS ASSOCIATED WITH HUMAN PAPILLOMA VIRUSES | LOMA LINDA UNIVERSITY (US) | 2017-01-19 | — | — | WO | claimed |
| US-6251280-B1 | A TEMPLATE MOLECULE IS BOUND TO ONE END OF BIFUNCTIONAL LIGANDS TO FORM A COMPLEX PRIOR TO BINDING OF THE BIFUNCTIONAL LIGANDS TO THE SUBSTRATE. | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2001-06-26 | — | — | US | claimed |
| US-5317014-A | Analgesics, antiinflammatory agents, antagonist, antiallergens or gastrointestinal disorders | ADIR ET COMPAGNIE (FR) | 1994-05-31 | — | — | US | claimed |
| US-5262537-A | Treatment of nausea and vomiting | ANAQUEST, INC. (US) | 1993-11-16 | — | — | US | claimed |
| EP-0517589-A2 | Tachykinin derivatives, their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-12-09 | — | — | EP | claimed |
| EP-0104041-B1 | ENZYME INHIBITORS | Aktiebolaget Hässle (SE) | 1988-07-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070153-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASES | ACE, AGT, AGTR2 | EGLN1 681/4885KDM4E 4745/4885ALDH1A1 2624/4885 |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | EGLN1 4480/4885KDM4E 4852/4885ALDH1A1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.